Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Illumina (NASDAQ:ILMN) gained $9.57 (16%) to $70.02 on Thursday after the microarray and genetic services company agreed to pay Affymetrix (NASDAQ:AFFX)
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury